Evaluation of the effect of Lactobacillus reuteri V3401 on biomarkers of inflammation, cardiovascular risk and liver steatosis in obese adults with metabolic syndrome: a randomized clinical trial (PROSIR).
Randomized controlled trial · BMC Complement Altern Med · 2018. Source record refreshed; an explanation has not been reviewed.
About this paper
This page identifies the publication and its source. A checked explanation of its findings is not yet available.
Reading this record
Checking bibliographic metadata does not verify a study’s conclusions or any advice previously linked to it.
Publication details
Evaluation of the effect of Lactobacillus reuteri V3401 on biomarkers of inflammation, cardiovascular risk and liver steatosis in obese adults with metabolic syndrome: a randomized clinical trial (PROSIR).
Tenorio-Jiménez C, Martínez-Ramírez MJ, Tercero-Lozano M et al.
BMC Complement Altern Med · 2018
- PubMed ID
- 30453950
- Record checked
A checked publication record confirms source details. It does not verify a health claim or assess the quality of the study. Our approach.
Keep your place in the research.
Save this source or mark it as read.